These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2693499)

  • 1. Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity.
    Wallin JD; Frishman WH
    J Clin Pharmacol; 1989 Dec; 29(12):1057-68. PubMed ID: 2693499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism.
    Sybertz EJ; Watkins RW
    Am J Cardiol; 1989 Jun; 63(19):3I-6I. PubMed ID: 2567112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.
    Lalonde RL; Tenero DM; Kazierad DJ
    Pharmacotherapy; 1990; 10(1):15-28. PubMed ID: 2179899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S12-7. PubMed ID: 2464093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of antihypertensive action of dilevalol compared with that of "cardioselective" beta-blocking agents.
    Strom JA; Vidt DG; Bugni W; Atkins J; Fouad-Tarazi F; Cubbon J; Poland MP
    Am J Cardiol; 1989 Jun; 63(19):25I-33I. PubMed ID: 2729125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.
    Baba T; Murabayashi S; Aoyagi K; Ishizaki T
    Eur J Clin Pharmacol; 1988; 35(1):9-15. PubMed ID: 2905992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
    Chrisp P; Goa KL
    Drugs; 1990 Feb; 39(2):234-63. PubMed ID: 2184002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of dilevalol and propranolol on systemic and regional haemodynamics in healthy volunteers at rest and during exercise.
    Bellissant E; Annane D; Thuillez C; Giudicelli JF
    Eur J Clin Pharmacol; 1994; 47(1):39-47. PubMed ID: 7988622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.
    Watkins RW; Sybertz EJ; Cook J; Pula K; Cedeno K; Tedesco RP; McLeod R
    Arch Int Pharmacodyn Ther; 1989; 302():158-73. PubMed ID: 2576892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity.
    Cook ME; Wallin JD; Clifton GG; Poland M
    Clin Pharmacol Ther; 1988 Apr; 43(4):393-9. PubMed ID: 3356083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of left ventricular hypertrophy in treated hypertensive patients with dilevalol and metoprolol--a double blind randomized study.
    Glasser SP; Koehn DK; Powell R
    J Clin Pharmacol; 1989 Sep; 29(9):791-7. PubMed ID: 2572609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacodynamics of dilevalol.
    Riddell JG
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():39-44. PubMed ID: 2370642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):635-42. PubMed ID: 2668352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravenous dilevalol with placebo in moderate hypertension.
    Winer N; Blasucci DJ; Medakovic M
    Clin Pharmacol Ther; 1989 Oct; 46(4):445-50. PubMed ID: 2551560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dilevalol, metoprolol and atenolol on left ventricular mass and function in nonelderly and elderly hypertensive patients.
    Frishman WH; Glasser SP; Strom JA; Schoenberger JA; Liebson P; Poland MP
    Am J Cardiol; 1989 Jun; 63(19):69I-74I. PubMed ID: 2567114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dilevalol compared with propranolol and placebo for systemic hypertension.
    Schoenberger JA; Frishman WH; Wallin JD; Gorwit J; Davidov ME; Michelson EL; Bedsole GD; Cubbon J; Poland MP
    Am J Cardiol; 1989 Jun; 63(19):45I-49I. PubMed ID: 2658529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renal function and blood pressure effects of dilevalol in the normotensive and hypertensive elderly.
    Clifton GG; Cook ME; Poland M; Wallin JD
    J Clin Pharmacol; 1989 Jul; 29(7):603-8. PubMed ID: 2760254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.